Swarm Oncology is pleased to announce a strategic partnership with Cellex Cell Professionals, a leading CDMO specialising in cell and gene therapy. This partnership will focus on advancing Swarm's innovative T cell therapies, designed to overcome the limitations of current immunotherapies in treating solid cancers, toward clinical trials in 2026. Cellex will provide critical support by supplying cellular starting material, overseeing process transfer and GMP manufacturing, ensuring quality control, and comprehensive regulatory compliance support. By leveraging Cellex's expertise and specialised infrastructure, this partnership aims to accelerate clinical timelines and enhance scalability, with the goal of bringing Swarm's innovative T-cell therapies to patients in need. To find out more, read our full press release here: https://lnkd.in/e5YRfcZw #SwarmOncology #CancerResearch #Immunology #Innovation #Cellex #Partnership #Oncology
Swarm Oncology
Biotechnology Research
We develop cell therapies to drive metastatic cancer into remission.
About us
Swarming cancer with personalised T cells.
- Website
-
https://swarmoncology.bio/
External link for Swarm Oncology
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Specialties
- Biotechnology, Life Sciences, Cell Therapy, Immunotherapy, Oncology, Cancer Therapeutics, Therapeutics, and Immuno-Oncology
Employees at Swarm Oncology
Updates
-
We are thrilled to announce the launch of Swarm Oncology today, unveiling our breakthrough Swarm-T platform for the treatment of solid cancers. Co-founded by Professor John Campbell, renowned T cell therapy manufacturing expert and immunologist and Delin Ventures, Swarm Oncology is led by newly appointed CEO Martin Olin, who brings over 25 years of executive leadership experience in the pharmaceutical and biotechnology industries. Swarm Oncology is developing novel, potent T cell therapies addressing the key limitations of current immunotherapy approaches. By leveraging immune system priming with proprietary ex vivo cell processing to generate unprecedented large number of T cells, our aim is to drive solid cancers into long-term remission and significantly improve treatment outcomes for patients living with cancer. To find out more, read our full press release here: https://lnkd.in/enVwiPyg #SwarmOncology #CancerResearch #Immunology #Innovation #CellTherapy #Oncology
-